HTB

HIV 7 Glasgow 2004

7th International Congress on Drug Therapy in HIV Infection (ICDTHI), 14-18 November 2004, Glasgow

Nandrolone decanoate combats HIV-related weight loss: results from three randomised studies

Atazanavir boosts intracellular saquinavir levels: data on important new dual-boosted regimen

Marked variability in plasma atazanavir levels: importance of ritonavir boosting and TDM

Effective switching to atazanavir/ritonavir in clinical practice

Ritonavir boosting may not overcome interaction between atazanavir and nevirapine

Nevirapine associated adverse events in a cohort of pregnant women

Higher nevirapine doses for children leads to better outcome

TDM in Ugandan study highlights importance of refridgerated ritonavir

Responses to TB treatment in HIV positive and HIV negative patients in the UK

800mg efavirenz may not be needed with rifampicin-based TB regimens, especially in African patients

EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects

Lower d4T dose maintains virologic suppression and CD4 increases